The mean age was 76 (range, 68-83) years, and 57% were men. Results: A total of 36 studies met criteria for inclusion, with a total of 1832 patients (967 receiving 4-factor prothrombin complex concentrate 525, andexanet alfa 340, idarucizumab).

The primary safety end points were all-cause mortality and thromboembolic events after the reversal agent.

Main Outcomes and Measures: The primary outcome was proportion with anticoagulation reversed. Data were pooled using the random-effects model.

Two reviewers independently selected the studies and abstracted data. Data Extraction and Synthesis: Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used for abstracting data and assessing data quality and validity. All nonhuman studies and case reports, studies evaluating patients with ischemic stroke requiring anticoagulation reversal or different dosing regimens of DOAC reversal agents, and mixed study groups with DOAC and warfarin were excluded. Study Selection: The eligibility criteria were (1) adult patients (age ≥18 years) with ICH receiving treatment with a DOAC, (2) reversal of DOAC, and (3) reported safety and anticoagulation reversal outcomes. Data Sources: PubMed, MEDLINE, The Cochrane Library, Embase, EBSCO, Web of Science, and CINAHL databases were searched from inception through April 29, 2022. Objective: To evaluate the safety and outcomes of DOAC reversal agents among patients with ICH. The safety and outcome data of DOAC reversal agents in ICH are limited. Importance: Direct oral anticoagulant (DOAC)-associated intracranial hemorrhage (ICH) has high morbidity and mortality.

Idarucizumab cost